Management of Patients With Aggressive Nonmelanoma Skin Cancers

Nonmelanoma skin cancers (NMSCs), which encompass a variety of cutaneous malignancies, are frequently managed with surgery, radiation therapy, cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. In this tumor board–style forum, a panel of experts used several case studies as a basis to review these approaches and to describe existing clinical challenges. The current NCCN Guidelines for NMSC, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of NMSCs, also provide key considerations and recommendations for the treatment of this patient population.

Disclosures: Dr. Thomas has disclosed serving as a scientific advisor for Merck & Co., Inc., Regeneron Pharmaceuticals, and sanofi-aventis U.S. Dr. Wong has disclosed serving as a scientific advisor for Bristol-Myers Squibb Company, Castle Biosciences, Inc., EMD Serono, Exicure, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc. Dr. Bishop has disclosed having no relevant financial relationships.

Correspondence: Valencia D. Thomas, MD, MHCM, The University of Texas MD Anderson Cancer Center, 6655 Travis Street, Suite 650, Houston, TX 77030. Email: vthomas@mdanderson.org; Michael K. Wong, MD, PhD, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 0430, Houston, TX 77004. Email: MKWong@mdanderson.org; and Andrew J. Bishop, MD, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. Email: abishop2@mdanderson.org
  • 1.

    Que SKT, Zwald FO, Schmults CD, et al. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Derm 2018;78:237247.

  • 2.

    Schmults CD, Blitzblau R, Aasi SZ, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Squamous Cell Skin Cancer. Version 1.2022. Accessed April 14, 2022. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 3.

    Schmults CD, Blitzblau R, Aasi SZ, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal Cell Skin Cancer. Version 2.2022. Accessed April 14, 2022. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 4.

    Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 2016;21:12181229.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Dinehart MS, McMurray S, Dinehart SM, et al. L-carnitine reduces muscle cramps in patients taking vismodegib. SKIN J Cut Med 2018;2:9095.

  • 6.

    Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after Hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021;22: 848857.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th Edition AJCC Staging System. Ann Surg Oncol 2016;23:35643571.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Fitzgerald TL, Dennis S, Kachare SD, et al. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg 2015;81:802806.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mayer JE, Swetter SM, Fu T, et al. Screening, early detection, education, and trends for melanoma. J Am Acad Derm 2014;71:599846.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 400 400 400
PDF Downloads 141 141 141
EPUB Downloads 0 0 0